CY1123187T1 - Θεραπευτικες μεθοδοι που αφορουν βλαστοκυτταρα καρκινου - Google Patents

Θεραπευτικες μεθοδοι που αφορουν βλαστοκυτταρα καρκινου

Info

Publication number
CY1123187T1
CY1123187T1 CY20201100427T CY201100427T CY1123187T1 CY 1123187 T1 CY1123187 T1 CY 1123187T1 CY 20201100427 T CY20201100427 T CY 20201100427T CY 201100427 T CY201100427 T CY 201100427T CY 1123187 T1 CY1123187 T1 CY 1123187T1
Authority
CY
Cyprus
Prior art keywords
stem cells
cancer stem
methods involving
therapeutic methods
melanoma
Prior art date
Application number
CY20201100427T
Other languages
English (en)
Inventor
Markus H. Frank
Natasha Y. Frank
Original Assignee
The Brigham And Women´S Hospital, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Brigham And Women´S Hospital, Inc. filed Critical The Brigham And Women´S Hospital, Inc.
Publication of CY1123187T1 publication Critical patent/CY1123187T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/122—Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)

Abstract

Αποκαλύπτονται γονίδια που είναι δυσρυθμισμένα σε βλαστοκύτταρα καρκίνου (π.χ., βλαστοκύτταρα μελανώματος). Μέθοδοι που περιλαμβάνουν ρύθμιση (π.χ., διέγερση, αναστολή, κ.λπ.) της δραστικότητας των σχετικών με βλαστοκύτταρο καρκίνου γονίδια χρησιμοποιούνται για να θεραπεύονται άτομα που έχουν μελάνωμα. Γονίδια επιφάνειας κυττάρου τα οποία είναι προς τα πάνω ρυθμισμένα σε βλαστοκύτταρα καρκίνου στοχεύονται για την εκλεκτική απομόνωση, ανίχνευση και θανάτωση βλαστοκυττάρων καρκίνου σε μελάνωμα.
CY20201100427T 2008-11-14 2020-05-08 Θεραπευτικες μεθοδοι που αφορουν βλαστοκυτταρα καρκινου CY1123187T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11449008P 2008-11-14 2008-11-14
EP09826430.2A EP2356446A4 (en) 2008-11-14 2009-11-13 DIAGNOSTIC AND THERAPEUTIC METHODS RELATING TO CANCER STEM CELLS
PCT/US2009/006089 WO2010056332A1 (en) 2008-11-14 2009-11-13 Therapeutic and diagnostic methods relating to cancer stem cells

Publications (1)

Publication Number Publication Date
CY1123187T1 true CY1123187T1 (el) 2021-10-29

Family

ID=42170214

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201100427T CY1123187T1 (el) 2008-11-14 2020-05-08 Θεραπευτικες μεθοδοι που αφορουν βλαστοκυτταρα καρκινου

Country Status (9)

Country Link
US (2) US20110287034A1 (el)
EP (4) EP3734281A3 (el)
AU (2) AU2009314556B2 (el)
CA (1) CA2743464A1 (el)
CY (1) CY1123187T1 (el)
DK (1) DK3130923T3 (el)
ES (1) ES2796111T3 (el)
PT (1) PT3130923T (el)
WO (1) WO2010056332A1 (el)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3333182A1 (en) 2000-06-05 2018-06-13 The Brigham and Women's Hospital, Inc. A gene encoding a multidrug resistance human p-glycoprotein homologue on chromosome 7p15-21 and uses thereof
PL2772535T3 (pl) * 2006-05-31 2022-09-05 Children's Medical Center Corporation Mezenchymalne komórki macierzyste ABC5 dodatnie jako immunomodulatory
JP5889527B2 (ja) 2007-04-12 2016-03-22 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 癌療法のためのａｂｃｂ５標的化
CA2724322C (en) 2008-05-14 2019-07-16 Dermtech International Diagnosis of melanoma and solar lentigo by nucleic acid analysis
WO2010056332A1 (en) 2008-11-14 2010-05-20 The Brigham And Women's Hospital, Inc. Therapeutic and diagnostic methods relating to cancer stem cells
US11542328B2 (en) 2008-11-14 2023-01-03 The Brigham And Women's Hospital, Inc. Therapeutic and diagnostic methods relating to cancer stem cells
GB201018312D0 (en) * 2010-10-29 2010-12-15 Vib Vzw Metagene expression signature for prognosis of breast cancer patients
ES2788183T3 (es) 2011-04-28 2020-10-20 Sbi Biotech Co Ltd Anticuerpo anti-proteína tirosina fosfatasa de tipo receptor humana
US20130079241A1 (en) * 2011-09-15 2013-03-28 Jianhua Luo Methods for Diagnosing Prostate Cancer and Predicting Prostate Cancer Relapse
WO2013130748A1 (en) * 2012-02-29 2013-09-06 The Regents Of The University Of Michigan Prostate cancer markers and uses thereof
US20150023920A1 (en) * 2012-03-29 2015-01-22 Drexel University Novel compositions and methods for preventing or treating cancer metastasis
US9903870B2 (en) 2012-10-04 2018-02-27 The Wistar Institute Of Anatomy And Biology Methods and compositions for the diagnosis of ovarian cancer
EP2964238B1 (en) 2013-02-19 2021-01-13 Children's Medical Center Corporation Abcb5(+) stem cells for treating ocular disease
US20160018399A1 (en) 2013-03-08 2016-01-21 Mayo Foundation For Medical Education And Research Methods and materials for identifying and treating mammals having lung adenocarcinoma characterized by neuroendocrine differentiation
ES2892403T3 (es) 2013-05-10 2022-02-04 Childrens Medical Center Curación de heridas e ingeniería de tejidos
CA2935216C (en) 2013-12-30 2021-11-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Fusion genes associated with progressive prostate cancer
CN115684591A (zh) * 2014-01-28 2023-02-03 奎斯特诊断投资股份有限公司 用于在癌症中检测腺瘤-腺癌过渡的方法和组合物
US10517898B2 (en) 2014-11-20 2019-12-31 The Regents Of The University Of California Compositions and methods related to hematologic recovery
CN104502601B (zh) * 2014-12-03 2016-04-06 上海交通大学医学院附属上海儿童医学中心 Scn3a作为诊断动脉导管闭合或开放的标志物
EP3314021A4 (en) * 2015-06-24 2019-05-08 Mor Research Applications Ltd. HISTONE MODIFICATION AGENTS FOR THE DIAGNOSIS AND TREATMENT OF CANCER
WO2017027473A1 (en) 2015-08-07 2017-02-16 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Methods for predicting prostate cancer relapse
CN106370503A (zh) * 2016-08-31 2017-02-01 宁波同盛生物科技有限公司 有机速干封片剂
WO2018102775A1 (en) * 2016-12-02 2018-06-07 The Regents Of The University Of California Methods and kits for predicting cancer prognosis and metastasis
US20190033907A1 (en) * 2017-07-25 2019-01-31 Psemi Corporation Butterfly Universal Temperature Profile
CN107727849B (zh) * 2017-09-28 2020-04-21 河北工程大学 一种检测人体疲劳状态的方法
EP3752645A4 (en) 2018-02-14 2022-04-13 Dermtech, Inc. NEW GENE CLASSIFIERS AND THEIR USES IN NON-MELANOMA SKIN CANCERS
US11578373B2 (en) 2019-03-26 2023-02-14 Dermtech, Inc. Gene classifiers and uses thereof in skin cancers
CN111041028B (zh) * 2019-12-20 2024-05-17 陕西省人民医院 人ttll4基因的用途及相关产品
CN110967486B (zh) * 2019-12-27 2022-12-06 暨南大学 hnRNPC蛋白的S260位点磷酸化作为结直肠癌干性标记物的应用
CN115429796A (zh) * 2021-06-03 2022-12-06 同济大学 利鲁唑靶向治疗Wolfram综合征
CN115612745B (zh) * 2022-12-19 2023-03-21 北京大学人民医院 Ipo7在结直肠癌治疗及预后预测中的应用

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
EP0174810B1 (en) 1984-09-10 1993-07-21 HSC Research Development Corporation Multidrug resistance in mammalian cell lines and isolation of determinant glycoprotein dna
US4837306A (en) 1985-02-25 1989-06-06 The Ontario Cancer Institute Method for selecting hybridomas producing antibodies specific to the P-glycoprotein cell suface antigen and a cDNA clone encoding the C-terminal portion of the antigen
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5399483A (en) 1989-03-30 1995-03-21 Suntory Limited Expression of MDR-related gene in yeast cell
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5434075A (en) 1992-03-20 1995-07-18 Board Of Trustees Of The University Of Illinois Monoclonal antibody to a human MDR1 multidrug resistance gene product, and uses
DE69233087T2 (de) 1991-11-22 2003-12-24 Affymetrix Inc N D Ges D Staat Verfahren zur Herstellung von Polymerarrays
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
WO1994009363A1 (en) 1992-10-14 1994-04-28 Board Of Regents, The University Of Texas System Cancer diagnosis and therapy
WO1995024929A2 (en) 1994-03-15 1995-09-21 Brown University Research Foundation Polymeric gene delivery system
US5686578A (en) 1994-08-05 1997-11-11 Immunomedics, Inc. Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
JPH11510142A (ja) 1995-07-21 1999-09-07 ブラウン・ユニバーシティ・リサーチ・ファンデーション 核酸負荷ポリマー微粒子を使用した遺伝子治療法
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6152142A (en) 1997-02-28 2000-11-28 Tseng; Scheffer C. G. Grafts made from amniotic membrane; methods of separating, preserving, and using such grafts in surgeries
US6008002A (en) 1997-09-29 1999-12-28 Bodey; Bela Immunomagnetic detection and isolation of cancer cells
EP1062321B1 (en) 1998-03-13 2004-12-29 Osiris Therapeutics, Inc. Uses for humane non-autologous mesenchymal stem cells
US6368636B1 (en) 1998-03-18 2002-04-09 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
JP2002539849A (ja) 1999-03-26 2002-11-26 ホワイトヘッド インスチチュート フォアー バイオメディカル リサーチ ユニバーサルアレイ
WO2001014557A1 (en) * 1999-08-23 2001-03-01 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
CA2384981A1 (en) 1999-09-28 2001-04-05 Gentest Corporation P-glycoproteins and uses thereof
EP3333182A1 (en) 2000-06-05 2018-06-13 The Brigham and Women's Hospital, Inc. A gene encoding a multidrug resistance human p-glycoprotein homologue on chromosome 7p15-21 and uses thereof
DE60140252D1 (de) 2000-06-22 2009-12-03 Genentech Inc Agonistische monoklonale antikörper gegen trkc
EP1412387A2 (en) 2000-10-27 2004-04-28 Incyte Genomics, Inc. Transporters and ion channels
WO2002062968A2 (en) 2001-02-02 2002-08-15 The Regents Of The University Of Michigan Micro-tubular materials and cell constructs
US6905678B2 (en) 2001-07-07 2005-06-14 Crucell Holland B.V. Gene delivery vectors with cell type specificity for mesenchymal stem cells
PT2206517T (pt) * 2002-07-03 2023-11-07 Tasuku Honjo Composições de imunopotenciação contendo anticorpos anti-pd-l1
JP2006502110A (ja) 2002-07-03 2006-01-19 イミュノジェン・インコーポレーテッド 非放出Ｍｕｃ１およびＭｕｃ１６に対する抗体、およびその使用
ES2367430T3 (es) * 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
WO2005005601A2 (en) * 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
EP1702061A4 (en) 2003-11-24 2007-05-02 Univ Rockefeller METHOD FOR ISOLATING A SLOW CYCLE, PLURIPOTENT CELL, REGENERATING SPONTANEOUSLY
CA3218940A1 (en) * 2004-11-12 2006-05-18 Cambridge University Technical Services Ltd. Methods and means related to cancer stem cells
ES2427646T5 (es) * 2005-05-09 2017-08-22 Ono Pharmaceutical Co., Ltd. Anticuerpos monoclonales humanos contra muerte programada 1 (PD1) y métodos para el tratamiento del cáncer mediante el uso de anticuerpos anti-PD-1 solos o combinados con otros agentes inmunoterapéuticos
KR101600225B1 (ko) * 2005-06-08 2016-03-04 다나-파버 캔서 인스티튜트 인크. 예정 세포사 1(ｐｄ-1) 경로를 억제함으로써 지속 감염 및 암을 치료하기 위한 방법 및 조성물
CA2612021A1 (en) * 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2006135886A2 (en) * 2005-06-13 2006-12-21 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
IL286053B2 (en) 2005-10-18 2023-03-01 Nat Jewish Health A process for making red blood cells using immortal hematopoietic stem cells and erythropoietin
US20090324618A1 (en) * 2006-03-24 2009-12-31 Armstrong Scott A Novel signature self renewal gene expression programs
PL2772535T3 (pl) 2006-05-31 2022-09-05 Children's Medical Center Corporation Mezenchymalne komórki macierzyste ABC5 dodatnie jako immunomodulatory
US20100009858A1 (en) * 2006-07-28 2010-01-14 Chundsell Medicals Ab Embryonic stem cell markers for cancer diagnosis and prognosis
EP2094719A4 (en) * 2006-12-19 2010-01-06 Genego Inc NEW PROCEDURES FOR THE FUNCTIONAL ANALYSIS OF EXPERIMENTAL HIGH-PERFORMANCE DATA AND IDENTIFIED GENDER GROUPS THEREOF
JP5889527B2 (ja) * 2007-04-12 2016-03-22 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 癌療法のためのａｂｃｂ５標的化
US20110046067A1 (en) 2007-06-22 2011-02-24 Intradigm Corporation COMPOSITIONS COMPRISING HUMAN EGFR-siRNA AND METHODS OF USE
JP5932217B2 (ja) 2007-07-12 2016-06-08 ジーアイティーアール， インコーポレイテッド Ｇｉｔｒ結合分子を使用する併用療法
WO2009024531A1 (en) * 2007-08-17 2009-02-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating and diagnosing hematologic malignancies
JP2011518313A (ja) * 2008-01-15 2011-06-23 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ 急性骨髄性白血病幹細胞のマーカー
WO2009097270A2 (en) * 2008-01-28 2009-08-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of determining breast cancer risk
WO2010056332A1 (en) 2008-11-14 2010-05-20 The Brigham And Women's Hospital, Inc. Therapeutic and diagnostic methods relating to cancer stem cells
EP2964238B1 (en) 2013-02-19 2021-01-13 Children's Medical Center Corporation Abcb5(+) stem cells for treating ocular disease
ES2892403T3 (es) 2013-05-10 2022-02-04 Childrens Medical Center Curación de heridas e ingeniería de tejidos

Also Published As

Publication number Publication date
EP3978928A1 (en) 2022-04-06
US20110287034A1 (en) 2011-11-24
ES2796111T3 (es) 2020-11-25
US20160009804A1 (en) 2016-01-14
DK3130923T3 (da) 2020-05-11
AU2016253648A1 (en) 2016-11-24
WO2010056332A1 (en) 2010-05-20
EP3734281A2 (en) 2020-11-04
EP3734281A3 (en) 2021-01-27
EP2356446A1 (en) 2011-08-17
EP3130923A1 (en) 2017-02-15
EP2356446A4 (en) 2014-03-19
AU2009314556B2 (en) 2016-08-04
US10316085B2 (en) 2019-06-11
AU2016253648B2 (en) 2019-05-02
CA2743464A1 (en) 2010-05-20
EP3130923B1 (en) 2020-02-12
PT3130923T (pt) 2020-06-17
AU2009314556A1 (en) 2011-06-30

Similar Documents

Publication Publication Date Title
CY1123187T1 (el) Θεραπευτικες μεθοδοι που αφορουν βλαστοκυτταρα καρκινου
CY1120523T1 (el) Συνδυαστικη θεραπεια με υαλουρονιδαση και στοχευμενο προς τον ογκο ταξανιο
CY1114006T1 (el) Τοπικα σκευασματα συνενζυμου q10 και μεθοδοι χρησης
CY1123404T1 (el) Αντι-girt αντισωματα
CY1120257T1 (el) ΠΥΡΡΟΛΟ[2,3b]ΠΥΡΙΔΙΝ-4-ΥΛΑΜΙΝΕΣ ΚΑΙ ΠΥΡΡΟΛΟ[2,3b]ΠΥΡΙΜΙΔΙΝ-4-ΥΛΑΜΙΝΕΣ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΚΙΝΑΣΩΝ JANUS
CY1120961T1 (el) Δοσολογικες μορφες απο του στοματος που περιλαμβανουν αντιαιμοπεταλιακο παραγοντα και αναστολεα οξεος
CY1121097T1 (el) Ανθρωπινα αντισωματα κατα toy gfr 3 και μεθοδοι χρησης αυτων
CY1117445T1 (el) Παραγωγα φωσφοραμιδικου της 5-φθορο-2´-δεοξυουριδινης για χρηση στην θεραπεια καρκινου
TR201909582T4 (tr) Pirimido[4,5-b]indol türevleri ve hematopoetik kök hücrelerinin ekspresyonunda bunlarin kullanimi.
EA201791843A3 (ru) Способы повышения эффективности folr1 терапии рака
NI201100189A (es) Compuestos y métodos para la modulación de las quinasas e indicaciones de los mismos
UA107667C2 (uk) Лікарські сполуки, що модулюють активність піруваткінази-м2, композиції на їх основі та застосування при лікуванні раку
MX351083B (es) Métodos para el tratamiento de trastornos oncológicos usando cambiadores epimetabólicos, moléculas intracelulares multidimensionales, o influenciadores ambientales.
CY1124331T1 (el) Αυξημενη βιοδιαθεσιμοτητα δραστικης ουσιας σε θεραπεια ναλτρεξονης
DK2252322T3 (da) Vaccinesammensætninger
WO2011137320A3 (en) Small molecule inhibitors of usp1 deubiquitinating enzyme activity
WO2011141823A3 (en) Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
MX364002B (es) Compuestos y composiciones activadoras de enzima.
EP2214495A4 (en) NATURALLY PHOTODYNAMIC ACTIVE SUBSTANCES AND ITS USE
MX2023000549A (es) Combinaciones para el tratamiento de neoplasias usando localizacion de celulas quiescentes e inhibidores de egfr.
GEP20156333B (en) (1,2,4)triazolo[4,3-a]quinoxaline derivatives as inhibitors of phosphodiesterases
MX2012008958A (es) Antagonista de neurogulina y usos de los mismos para el tratamiento contra el cancer.
NZ703411A (en) Use of markers in the diagnosis and treatment of prostate cancer
WO2009043022A3 (en) Individualized cancer treatments
ATE456053T1 (de) Na+, k+-atpase-expression bei zervixdysplasie und krebs